Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT05323149
Recruiting Phase 3

Dexamethasone in Traumatic Brain Injury

NCT05323149 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Phase 3
Started
2022-05-18
Last updated
2026-09-16

Condition(s) studied

Inflammatory Response

Investigational drug(s) / intervention(s)

SalineDexamethasone →

Saline: Giving saline 0.9% (loading dose of 5 ml of saline 0.9%, followed by a 5 ml of maintenance saline 0.9% dose every 6 hours for 48 h).

Dexamethasone: Giving Dexamethasone (loading dose of 10 mg dilutedin 5 ml saline, followed by a 8 mg in 5 ml saline of maintenance dose every 6 hours for 48 h).

Study summary

In this study, our aim is to investigate the role of Dexamethasone for modulating the inflammation in patients with traumatic brain injury (TBI).

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Isolated traumatic brain injury patients (mild or moderate cases) * GCS \> 8 * non penetrating TBI in 8 hours onset * Age ≥ 18 years Exclusion Criteria: * Patient in cardiac arrest * Patients with coagulopathies * All diabetic patients * Renal failure patients * pregnancy * Patient refusal to participate

Primary outcome measure(s)

  • Percentage of patients with decreased the inflammatory response — 48 hours post-interventional (either placebo or Dexamethasone)
    Percentage of patients with decreased the inflammatory response, as assessed by NLR measurements

Trial sites (1)

FacilityCityRegionStatus
Assiut university hospital Asyut Assuit Recruiting

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05323149 on ClinicalTrials.gov ↗ ← All trials in Egypt